Healio spoke with Chakra Chaulagain, MD, about a retrospective observational study on prescribing patterns and outcomes of bortezomib in newly diagnosed patients with multiple myeloma presented at ASH Annual Meeting and Exposition.
The study included 2,522 patients aged 18-70 years who were newly diagnosed with multiple myeloma from 2017 to 2022 who received a first-line bortezomib-containing regimen and had at least 6 months of follow-data available and two clinical visits.
Researchers found that prescribing patterns for bortezomib have shifted toward the use of once-weekly bortezomib, but
